Taipei Medical University Institutional Repository:Item 987654321/64554
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 45422/58598 (78%)
造访人次 : 2549327      在线人数 : 296
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/64554


    题名: 佳世達私募換股大江基因醫學之關鍵成功因素探討
    Discussion on the key success factors of Qisida’s private equity exchange for Dajiang Genetic Medicine
    作者: 王怡
    WANG, YI
    贡献者: 管理學院生物科技高階管理碩士在職專班
    許怡欣
    关键词: 私募;換股;大江基因醫學;佳世達;基因檢測;精準醫療;生物科技
    private equity;stock exchange;Dajiang Genetic Medicine;Qisda;genetic testing;precision medicine;biotechnology
    日期: 2024-06-29
    上传时间: 2024-11-06 10:41:43 (UTC+8)
    摘要: 佳世達以私募換股結盟大江基因醫學，擴大其基因檢測專利業務，並積極參與精準醫療產業的發展。大江基因醫學在基因檢測產業，擁有相當出色的技術與研發優勢，累積長期研發經驗和技術能量，具有龐大的研發和專利技術儲備，佳世達以私募換股大江基因醫學，結合其技術優勢、成熟的營運管理和品牌影響力，提升自身在跨足生物科技產業的競爭優勢。
    佳世達私募換股大江基因醫學，符合國際產業發展的潛在趨勢。近年來，生物科技研發逐步成為全球經濟競爭力中，新的增長與發展點。透過私募換股，佳世達不僅可以快速提升其在基因檢測專利業務上的實力，更可以提升公司在精準醫療產業中的地位，並希望具備國際間推動生物科技產業成長的重要力量。
    佳世達私募換股大江基因醫學的成功範例，加快佳世達在精準醫療產業中的發展，更標示著電子科技跨領域創新日臻進步，生物科技產業將是未來的重要發展領域之一，佳世達採取私募換股的決定，有助於提升臺灣在全球生物科技產業中的地位與競爭力，提供其他產業順利跨領域合作雙贏的借鏡。
    Qisda has formed an alliance with Dajiang Genetic Medicine through a share exchange to expand its genetic testing patent business and actively participate in the development of the precision medicine industry. Dajiang Genetic Medicine has excellent technology and R&D advantages in the genetic testing industry. It has accumulated long-term R&D experience and technical energy, and has a huge R&D and patented technology reserve. Qisda exchanged private equity for shares in Dajiang Genetic Medicine, combining its technical advantages and maturity. operation management and brand influence to enhance its competitive advantage in the biotechnology industry.
    Qisda's private equity exchange for shares in Dajiang Genetic Medicine is in line with the potential trend of international industry development. In recent years, biotechnology research and development has gradually become a new growth and development point in global economic competitiveness. Through private placement and stock exchange, Qisda can not only quickly improve its strength in the genetic testing patent business, but also enhance the company's position in the precision medicine industry, and hopes to become an important force in promoting the growth of the biotechnology industry internationally.
    The successful example of Qisda's private equity swap for Dajiang Genetic Medicine has accelerated Qisda's development in the precision medicine industry, and also marked the progress of cross-field innovation in electronic technology. The biotechnology industry will be one of the important development areas in the future. Qisda has adopted The decision to conduct a private equity exchange will help enhance Taiwan's status and competitiveness in the global biotechnology industry, and provide other industries with a reference for smooth cross-field cooperation and win-win results.
    描述: 碩士
    指導教授：許怡欣
    口試委員：楊雅婷
    口試委員：陳炳全
    口試委員：許怡欣
    附注: 論文公開日期：2029-07-23
    数据类型: thesis
    显示于类别:[生物科技高階管理碩士專班] 博碩士論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML0检视/开启


    在TMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈